LYONS GARY A, DIR, reported an open-market or private sale at Travere Therapeutics, Inc. involving 900.000000 shares for an estimated $57470.13. Reported holdings after the transaction were 61500.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
No officer title
This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares…
The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of…
The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of…
The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of…
The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of…
The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of…
The stock option is fully vested and exercisable.
0 other filings
0 recent txs